CommercialCoverageMedium impact
08.00.74z, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Updated policy for intravitreal injection of VEGF antagonists, VEGF biosimilars, and combination VEGF/Angiopoietin-2 inhibitors effective July 1, 2025. This is a commercial insurance policy update that will affect billing and coverage for these specialized eye injection procedures.
Action Required
By July 1, 2025: Billing team must review the full policy details at the provided URL to understand specific changes to VEGF injection coverage requirements. Update billing procedures and prior authorization protocols for intravitreal VEGF injections based on the complete policy content. Ophthalmology staff should be notified of any new documentation or coverage requirements.